Validation of a Predictive Score of Acute Chest Syndrome (Presev2)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03032055|
Recruitment Status : Unknown
Verified January 2017 by Soutien aux Actions contre les Maladies du Globule Rouge.
Recruitment status was: Recruiting
First Posted : January 26, 2017
Last Update Posted : January 26, 2017
Vaso-Occlusive Crisis (VOC), the most common manifestation of sickle cell disease (SCD), is the first cause of death, particularly when complicated by an acute chest syndrome (ACS).
The PRESEV score could help the physicians to better manage VOC and could be used for future therapeutic trials. This predictive score of secondary ACS has to be validated in a multicenter international study.
|Condition or disease|
|Vaso Occlusive Crisis Acute Chest Syndrome|
International multicentre prospective observational study.
Prediction of an ACS within 15 days after admission by the PRESEV2 score at arrival.
Validation of a Predictive Score of Acute Chest Syndrome (Presev2) associates a categorical pain score of the spine /or pelvis and 3 biological parameters: Reticulocytes, Leucocytes and Hemoglobin.
ACS is defined by crepitant or bronchial breathing or the association of new radiologic infiltrate and chest pain
- Children (>2 years) and adults
- Male and Female
- Homozygous SCD patients
- The patient can only be included once
- VOC admitted at the emergency unit (a severe VOC is defined as pain or tenderness affecting at least one part of the body (e.g. limbs, ribs, sternum, head (skull), spine and/or pelvis) that required hospitalization and opioids (level 3), and is not attributable to other causes.
- Patient has health care insurance (in Europe)
- Written consent given after being informed of the purpose, progress and potential risks
- No inaugural Acute Chest Syndrome
- Homeless patients
- Deprived of their liberty by a court or administrative order or under guardianship
- Unable to understand the purpose and conditions of carrying out the study, unable to give consent
STUDY SCHEDULE Screening and inclusion once patients are admitted at the accident and emergency department or medical day unit.
Inclusion visit (day 1) Once admitted at the accident and emergency department, the patient will be informed about the protocol and asked to participate in the study. Informed consent will be obtained according to local regulations by signing the informed consent form. The inclusion and non-inclusion criteria will be verified.
Demographic data, current and previous treatments taken within one month, and medical history will be recorded.
The following parameters of the score will be collected:
Reticulocytes and/or leucocytes counts, urea (mmol/L) and Categorical pain score.
The Score is adjusted with Hydroxyurea treatment (Yes/No) and Hb level (g/dL). Plasmodium falciparum test will be performed only in Africa. Hemoculture if fever (>38°C) is recorded within the 2 first days after admission.
Temperature, Blood pressure, Oxygen saturation, Respiratory rate, Visual analogue score will be recorded.
STUDY DURATION Inclusion period: 2 years Per patient: 15 days Total duration of the study: 2 years
|Study Type :||Observational|
|Estimated Enrollment :||800 participants|
|Official Title:||Validation of a Predictive Score of Acute Chest Syndrome|
|Study Start Date :||January 2016|
|Estimated Primary Completion Date :||January 2018|
|Estimated Study Completion Date :||January 2018|
Patients who won't develop a secondary Acute chest syndrome during a vaso occlusive crisis within 15 days after admission.
Secondary Acute chest syndrome is defined by a new auscultatory abnormality (crepitation or bronchial breathing) OR the association of a new radiologic infiltrate and chest pain or decreased breath sounds .
A vaso-occlusive crisis is a common painful complication of sickle cell anemia in adolescents and adults. It is a form of sickle cell crisis. Sickle cell anemia - most common in those of African, Hispanic, and Mediterranean origin - leads to sickle cell crisis when the circulation of blood vessels is obstructed by sickled red blood cells, causing ischemic injuries.
Patients who will develop a secondary acute chest syndrome during a vaso occlusive crisis within 15 days after admission.
Secondary Acute chest syndrome is defined by a new auscultatory abnormality (crepitation or bronchial breathing) OR the association of a new radiologic infiltrate AND chest pain or decreased breath sounds .
A vaso-occlusive crisis is a common painful complication of sickle cell anemia in adolescents and adults.It is a form of sickle cell crisis. Sickle cell anemia - most common in those of African, Hispanic, and Mediterranean origin - leads to sickle cell crisis when the circulation of blood vessels is obstructed by sickled red blood cells, causing ischemic injuries.
- Primary Outcome Measure of Validation of a Predictive Score of Acute Chest Syndrome [ Time Frame: 2 years ]The primary outcome mesure is the occurrence of an ACS defined by crepitant or bronchial breathing or the association of new radiologic infiltrats and chest pain during the first 15 days of hospitalization for Vaso Occlusive Crisis
- Secondary Outcome Measures: Validation of a Predictive Score of Acute Chest Syndrome [ Time Frame: 2 years ]
Association of the PRESEV 2 score with the following parameters collected for each patient:
- The number of days of hospitalization
- Blood transfusion requirement
- The number of hospitalization in intensive care unit
Biospecimen Retention: Samples With DNA
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03032055
|Contact: DJOUMAD Sabrina, Master's||33 (1) email@example.com|
|Contact: BERKENOU Jugurtha, Master's||33 (1) firstname.lastname@example.org|
|Henri Mondor Hospital||Recruiting|
|Creteil, France, 94000|
|Contact: Pablo BARTOLUCCI, Professor 33 (1) 49817406 email@example.com|
|Principal Investigator:||BARTOLUCCI Pablo, MD PhD, Pr||APHP, UPEC, INSERM|